Docking-based classification models for exploratory toxicology studies on high-quality estrogenic experimental data.

BACKGROUND The ethical and practical limitation of animal testing has recently promoted computational methods for the fast screening of huge collections of chemicals. RESULTS The authors derived 24 reliable docking-based classification models able to predict the estrogenic potential of a large collection of chemicals provided by the US Environmental Protection Agency. Model performances were challenged by considering AUC, EF1% (EFmax = 7.1), -LR (at sensitivity = 0.75); +LR (at sensitivity = 0.25) and 37 reference compounds comprised within the training set. Moreover, external predictions were made successfully on ten representative known estrogenic chemicals and on a set consisting of >32,000 chemicals. CONCLUSION The authors demonstrate that structure-based methods, widely applied to drug discovery programs, can be fairly adapted to exploratory toxicology studies.

[1]  C. Ottmann,et al.  Synthesis and Crystal Structure of a Phosphorylated Estrogen Receptor Ligand Binding Domain , 2010, Chembiochem : a European journal of chemical biology.

[2]  P B Sigler,et al.  Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  W. Cornell,et al.  Simulation of the different biological activities of diethylstilbestrol (DES) on estrogen receptor α and estrogen-related receptor γ , 2003 .

[4]  T. Colborn,et al.  Environmental estrogens: health implications for humans and wildlife. , 1995, Environmental health perspectives.

[5]  S. T. Cohn,et al.  ERbeta ligands. Part 5: synthesis and structure-activity relationships of a series of 4'-hydroxyphenyl-aryl-carbaldehyde oxime derivatives. , 2007, Bioorganic & medicinal chemistry letters.

[6]  Margaret Warner,et al.  Estrogen receptors: how do they signal and what are their targets. , 2007, Physiological reviews.

[7]  Ingo Muegge,et al.  Advances in virtual screening , 2006, Drug Discovery Today: Technologies.

[8]  M. Jacobs,et al.  In silico tools to aid risk assessment of endocrine disrupting chemicals. , 2004, Toxicology.

[9]  L. Giudice,et al.  Endocrine-disrupting chemicals: an Endocrine Society scientific statement. , 2009, Endocrine reviews.

[10]  W. Tong,et al.  QSAR Models Using a Large Diverse Set of Estrogens. , 2001 .

[11]  K. Korach,et al.  Estrogen Receptor-α Mediates Diethylstilbestrol-Induced Feminization of the Seminal Vesicle in Male Mice , 2012, Environmental health perspectives.

[12]  J. Gustafsson,et al.  Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. , 1998, Molecular pharmacology.

[13]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[14]  Ann Richard,et al.  ACToR--Aggregated Computational Toxicology Resource. , 2008, Toxicology and applied pharmacology.

[15]  C. Klinge,et al.  Resveratrol Acts as a Mixed Agonist / Antagonist for Estrogen Receptors a and b * , 2000 .

[16]  Wei Xu,et al.  Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. , 2011, Chemical research in toxicology.

[17]  J. Devillers,et al.  SAR and QSAR modeling of endocrine disruptors , 2006, SAR and QSAR in environmental research.

[18]  Jiangang Chen,et al.  Recent Evidence Regarding Triclosan and Cancer Risk , 2014, International journal of environmental research and public health.

[19]  J. Cline,et al.  Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis). , 2007, American journal of obstetrics and gynecology.

[20]  Angelo Carotti,et al.  An Integrated Approach to Ligand- and Structure-Based Drug Design: Development and Application to a Series of Serine Protease Inhibitors , 2008, J. Chem. Inf. Model..

[21]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[22]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[23]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[24]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[25]  Yankai Xia,et al.  The in Vitro estrogenic activities of triclosan and triclocarban , 2014, Journal of applied toxicology : JAT.

[26]  Angelo Carotti,et al.  Improving Quantitative Structure-Activity Relationships through Multiobjective Optimization , 2009, J. Chem. Inf. Model..

[27]  W. Cornell,et al.  Simulation of the different biological activities of diethylstilbestrol (DES) on estrogen receptor alpha and estrogen-related receptor gamma. , 2003, Biopolymers.

[28]  Samo Turk,et al.  Endocrine Disruptome - An Open Source Prediction Tool for Assessing Endocrine Disruption Potential through Nuclear Receptor Binding , 2014, J. Chem. Inf. Model..

[29]  G. Klebe.  Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.

[30]  Jorrit J Hornberg,et al.  Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how. , 2014, Drug discovery today.

[31]  Richard A. Friesner,et al.  Integrated Modeling Program, Applied Chemical Theory (IMPACT) , 2005, J. Comput. Chem..

[32]  Emilio Benfenati,et al.  REACH and in silico methods: an attractive opportunity for medicinal chemists. , 2014, Drug discovery today.

[33]  Philippe Lecomte,et al.  A review of dietary and non-dietary exposure to bisphenol-A. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[34]  Y Z Chen,et al.  Virtual screening methods as tools for drug lead discovery from large chemical libraries. , 2012, Current medicinal chemistry.

[35]  David Dix,et al.  Computational Toxicology as Implemented by the U.S. EPA: Providing High Throughput Decision Support Tools for Screening and Assessing Chemical Exposure, Hazard and Risk , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[36]  Cédric Merlot,et al.  Computational toxicology--a tool for early safety evaluation. , 2010, Drug discovery today.

[37]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[38]  Ivan Rusyn,et al.  Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches. , 2013, Toxicology and applied pharmacology.

[39]  G. Morris,et al.  Naturally occurring plant polyphenols as potential therapies for inherited neuromuscular diseases. , 2013, Future medicinal chemistry.

[40]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[41]  S. O. Mueller,et al.  Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice. , 2001, Current opinion in pharmacology.

[42]  I. Kano,et al.  ER-dependent estrogenic activity of parabens assessed by proliferation of human breast cancer MCF-7 cells and expression of ERalpha and PR. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[43]  Ann-Gerd Thorsell,et al.  Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators. , 2004, Journal of medicinal chemistry.

[44]  N. Kruijf,et al.  Contents of methyl‐, ethyl‐, propyl‐, butyl‐ and benzylparaben in cosmetic products , 1995, Contact dermatitis.

[45]  Ruben Abagyan,et al.  Nuclear hormone receptor targeted virtual screening. , 2003, Journal of medicinal chemistry.

[46]  R. Judson,et al.  The Toxicity Data Landscape for Environmental Chemicals , 2008, Environmental health perspectives.

[47]  Qingzhong Hu,et al.  Drug discovery for breast cancer and co-instantaneous cardiovascular disease: what is the future? , 2013, Future medicinal chemistry.

[48]  David A. Agard,et al.  Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism , 2002, Nature Structural Biology.

[49]  Emilio Benfenati,et al.  An alternative QSAR-based approach for predicting the bioconcentration factor for regulatory purposes. , 2014, ALTEX.